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a b s t r a c t
Backgr
ound: Health research agendas are ofte
n set by researchers or by industry and may not reflect the needs and priorities of end users. This prioritysetting partnership (PSP) for epilepsy was undertaken to identify the most pressing unanswered questions about epilepsy and seizures from the perspective of people with epilepsy (PWE) and their care providers.
Methods: Using the methodology developed by the James Lind Alliance (JLA), evidence uncertainties were
gathered via online surveys from stakeholders across Canada. Submissions were formed into summary
questions and checked against existing evidence to determine if they were true uncertainties. Verified
uncertainties were then ranked by patients, caregivers, and healthcare providers and a final workshop
was held to reach a consensus on the top 10 priorities.
Results: The final top 10 list reflects the priority areas of focus for research as identified by the Canadian
epilepsy community, including genetic markers for diagnosis and treatment, concerns about living with
the long-term effects of epilepsy, and addressing knowledge gaps in etiology and treatment approaches.
Conclusion: This project represents the first systematic evidence of patient- and clinician-centered
research priorities for epilepsy. The results of this priority-setting exercise provide an opportunity for
researchers and funding agencies to align their agendas with the values and needs of the epilepsy community in order to improve clinical outcomes and quality of life (QOL) for PWE.
Ó 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Epilepsy is one of the most common neurological conditions
worldwide. It is a complex, heterogenous disease that affects
Abbreviations: JLA, James Lind Alliance; PSP, priority-setting partnership;
REPRISE, reporting guideline for health research priority setting with stakeholders.
⇑ Corresponding author at: Department of Pharmacology and Toxicology, University of Toronto Medical Sciences Building, 1 King’s College Circle, Room 4207,
Toronto, Ontario M5S 1A8, Canada.
E-mail address: amaya.singh@utoronto.ca (A. Singh).

around 300,000 Canadians, and 20,000 are newly diagnosed each
year [1]. Although antiseizure medication can successfully control
seizures in approximately 70% of patients, treatment selection
remains challenging and epilepsy-related comorbidities represent
a substantial burden [2,3]. People with epilepsy (PWE) report high
usage of healthcare resources and significantly lower quality of life
(QOL) than individuals living with other chronic conditions [4,5].
Health inequalities among PWE and disparities in access to care
represent significant barriers to effective treatment [5,6]. Epilepsy
also carries an increased risk of premature death [7], and the

https://doi.org/10.1016/j.yebeh.2022.108673
1525-5050/Ó 2022 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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prevalence of social stigma and discrimination toward PWE continues to be a source of fear and distress [8–10]. Thus, the current
scope of epilepsy research is necessarily broad, and knowledge
gaps exist across the continuum of care. With limited funding
[11] and resources, it is critical to focus on addressing evidence
gaps that will have the largest impact on health-related QOL for
PWE. While shared decision-making has become an increasingly
important aspect of clinical care, the adoption of meaningful
patient engagement in research has yet to be normalized [12].
Health research agendas are often biased by vested researcher or
commercial interests, leading to a mismatch between the priorities
of researchers and those whom research is intending to serve
[13,14]. As such, there is growing acknowledgment of the need
to engage patients as partners in research and to direct funding
to those areas deemed most essential by end users. The James Lind
Alliance (JLA), a UK-based non-profit initiative supported by the
National Institute for Health Research, has developed a rigorous
methodology for increasing public engagement in research by consulting patients, caregivers, and healthcare providers regarding
their most pressing unanswered questions or treatment uncertainties [15]. Such priority-setting partnerships (PSPs) provide an
opportunity to increase the clinical relevance of research and
improve patient outcomes. Importantly, the JLA methodology gives
an equal voice to patients, caregivers, and clinicians to help ensure
that their needs are represented in health research agendas. In collaboration with the JLA, the Ontario Brain Institute (OBI) and its
epilepsy research program (EpLink) undertook a Canada-wide
PSP to identify and prioritize unanswered questions relating to epilepsy and seizures in pediatric and adult populations. To maintain
transparency and accountability, we have reported on the domains
as set out in the reporting guideline for health research priority
setting with stakeholders (REPRISE) [16].

2. Material and methods
Ethics approval was obtained from the Community Research
Ethics Office at the Centre for Community Based research in Waterloo, Ontario. This project was completed over 23 months (May
2019 to April 2021) and was overseen by an independent JLA advisor (KC). An overview of the JLA process is provided in Fig. 1.

2.1. Establishment of steering group
Based on their professional experience, the project team identified and reached out to established leaders in the Canadian epilepsy community, who in turn reached out to their contacts in
the patient and professional communities. In accordance with JLA
principles, steering group (SG) members brought with them
knowledge of epilepsy, an understanding of the epilepsy community, and access to networks of patients, caregivers, and clinicians.
The initial SG comprised five clinicians and seven community
members drawn from across Canada (see Fig. 2 for details). Community members were either PWE, caregivers, or members of
non-profit agencies. Steering group members were asked to
declare any potential conflicts of interest at the outset. The SG
met monthly and was responsible for overseeing and guiding the
priority-setting process. Members played an active role in setting
the scope of the project, determining how questions were categorized, and ensuring that the perspectives brought forward from the
community were accurately represented. The project team comprised the SG, the JLA advisor, and knowledge translation specialists from the OBI and EpLink. In addition, an Information
Specialist (IS) team led the dataset management and evidencechecking process with the assistance of the SG.

Fig. 1. Overview of JLA process.
2
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Fig. 2. Results of JLA process. *Due to personal and professional obligations, four members were unable to continue their participation and were replaced over the course of
the project. However, the composition of the group remained similar throughout, and the final group consisted of six clinicians and six community members.

a respondent could submit for each of the topic areas. Optional
demographic questions were included to help understand the
respondent profile, including respondent type, age, gender, ethnic
background, and province or territory. Eighty-eight partner organizations, including advocacy groups, professional organizations,
community agencies, and health research institutions, were identified by SG members. They were asked to promote the survey
through social media, newsletters, mailing lists, websites, blogs,
membership communications, or in clinics. Respondents were able
to provide their email address through a separate survey process if
they wished to receive future information about the study. Paper
copies were also mailed to epilepsy monitoring units and nonprofit community epilepsy agencies if requested by staff members.

2.2. Scope of project
This PSP focused on questions relating to the cause, diagnosis,
and treatment of epilepsy and seizures, as well as management
of day-to-day life and comorbidities. Questions related to healthcare policies, access to services, or treatment of epilepsy outside
of Canada were considered out of scope. Given that epilepsy is
often used interchangeably with the term ‘‘seizure disorder”, it
was determined that the survey language should refer to both
‘‘epilepsy” and ‘‘seizures”.
2.3. Gathering evidence uncertainties
An anonymous online survey, offered in both French and English, was created using the Research Electronic Data Capture (REDCap) system hosted by the Centre for Advanced Computing
(Kingston, Ontario) and posted on the Ontario Brain Institute’s
public website. In accordance with the JLA aims, eligible respondents included PWE and their caregivers, friends or family members, and healthcare providers. The initial survey consisted of
four open-ended questions where respondents were asked to submit their unanswered questions about epilepsy and seizures
(Table 1). There was no limit to the length or number of questions

2.4. Formation of summary questions and evidence checking
Each submitted question was assigned a unique identifier and
categorized first as in-scope or out-of-scope, and then subcategorized by topic. Many entries contained multiple questions
which were extracted individually where possible. In instances
where comments, statements, or personal anecdotes were
included, these remained in their original format and were given
an identifier if it was clear what the response intended to ask;
3
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using the PICO (Population, Interest, Context) framework and relevant search terms were established for each question. Literature
searches were carried out using five different databases (Cochrane,
Medline, EMBASE, CINAL, and SCOPUS) and any additional sources
suggested by the SG, such as the WHO. Study types included qualitative studies, case reports or case series with qualitative study
components, and review-level studies when possible. No date limitations were included, but searches were limited to English language publications. An uncertainty was deemed to be any
question that could not be answered by the described literature
review process.

Table 1
Initial survey questions.
Questions
1
2
3

4

What question(s) do you still have about the cause or diagnosis of
epilepsy and seizures?
What question(s) do you still have about the treatment of epilepsy and
seizures?
*What question(s) do you still have about managing day-to-day life with
epilepsy and seizures? (Examples include life at work or school, memory
problems, fear, stigma, or suicidal thoughts)
*What question(s) do you still have about managing the co-existing
conditions related to epilepsy and seizures? (Examples include
depression, anxiety, behavioral issues, or developmental disorders)

*
SG members felt that examples of co-existing conditions and day-to-day challenges would be helpful if provided despite the potential risk of influencing
responses.

2.5. Prioritization survey
The uncertainties were refined and reduced to produce a shortlist of questions for the interim prioritization survey, with the SG
advising on a number of questions that would be manageable to
survey respondents who experience seizures. Similar questions
from the same theme were combined, and some questions were
removed based on a low frequency of original submissions (<7).
Participants were recruited in the same manner as the first survey,
and partner organizations again promoted the survey among their
networks. Community epilepsy agencies were unable to distribute
paper copies due to COVID-19-related limitations on their inperson services. In the first section, respondents were asked to
select up to ten questions they most wanted researchers to
address. In the second section, respondents had the option to provide their demographic information, to help the SG understand the
respondent profile and target promotional activity toward groups
who were under-represented in survey responses. To determine
the final set of questions to move forward to the final workshop,
questions were ranked based on the frequency with which they
were chosen, with each response given one point. Rankings were
calculated separately for PWE/caregiver and health care provider
respondent groups to ensure equal influence on the shortlisting.
Questions were placed into rank order within each group and rankings were then merged to determine the final order. The top 16
questions were then brought forth to the final workshop.

otherwise, these responses were categorized as ‘‘question too
broad or unclear”. Similar questions were aggregated under larger
summary questions within each topic. Examples of the categorization process are provided in Table 2. The IS team was responsible
for creating summary questions from the initial submissions and
cross-referencing these questions with existing research to broadly
determine whether they were true uncertainties. Steering group
members guided the summary question development by assisting
with the interpretation of submissions, reviewing initial summary
questions, and determining the appropriateness of combining
questions.
In order to inform the evidence-checking strategy, questions
were organized by the IS team into three categories: quantitative,
qualitative, and mixed methods (qualitative and quantitative).
Questions that could be answered primarily through objective
measurement and numerical analysis were deemed quantitative,
while questions focusing on the knowledge and perceptions of
those being studied were categorized as qualitative. Questions that
could be answered using both approaches were considered mixed
methods.
The JLA defines a question as an uncertainty when no up-todate, reliable systematic reviews of research evidence addressing
the uncertainty exist, or when such reviews are inconclusive.
Accordingly, for quantitative questions, sources for evidence
checking included the following systematic reviews and existing
guidelines: (a) The Cochrane Database of Systematic Reviews; (b)
Cochrane Epilepsy; (c) Scottish International Guidelines Network
(SIGN), and National Institute for Health and Care Excellence
(NICE), as no relevant guidance exists from the Royal College of
Physicians and Surgeons of Canada as well as (d) The International
League Against Epilepsy and (e) the World Health Organization
(WHO). For qualitative questions, key components were identified

2.6. Final workshop
A two-day, virtual workshop was held to determine the final
prioritization. Community members were invited to send expressions of interest to participate in the workshop via an online form
that asked potential attendees about their personal and professional experiences with epilepsy and their reasons for wanting to
take part in the workshop. Attendees were selected to ensure a
diversity of interests, experience, clinical specialties, and geo-

Table 2
Classification of responses.
Category
Aggregation of similar
questions

Comments, statements or
personal anecdotes where
intended question is clear

Comments, statements or
personal anecdotes where
intended question is unclear

Examples of original submissions

Summary question or classification

 ‘‘Are multiple medications more effective?”
 ‘‘Is medication the best treatment?”
 ‘‘What is the long-term effectiveness of medication-based
treatments?”
‘‘My question it seems like his epilepsy gets treated and his depression
is his to manage through lifestyle changes but his depression is a
medical condition as well. There is no across the board treatment for
the coexisting condition of depression and epilepsy. It is treat the
epilepsy and lifestyle changes for the depression which don’t always
work.”
 ‘‘What is the impact on youth?”
 ‘‘We should develop better non-invasive treatments.”

4

Grouped under summary question: ‘‘How effective are
antiseizure drugs?”

Grouped under summary question: ‘‘What medical, non-medical
and community support methods can assist people who
experience seizures in managing depression/anxiety?”

Categorized as too broad or unclear
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graphic locations. Eleven community members with lived experience and eleven health or care professionals from across Canada
attended the workshop (Fig. 2). Participants were provided with
the list of questions and asked to rank them independently prior
to the meeting. During the workshop, all participants shared their
views and had the opportunity to hear the perspectives of others.
Using a nominal group technique, four trained JLA facilitators led
participants in group-level discussions and two rounds of prioritization, after which a top 10 list was reached by consensus.

Table 3
Demographics of respondents from initial and interim surveys.
Category

Initial
survey (%)

Interim
survey (%)

Total responses

516

590

255 (49.4)
74 (14.3)

251 (42.5)
83 (14.1)

113 (21.9)

147 (24.9)

46 (8.9)
8 (1.6)
10 (1.9)
10 (1.9)

97 (16.4)
7 (1.2)
<5 (<0.8)
<5 (<0.8)

6 (1.2)
19 (3.7)
7 (1.4)
<5 (<1.0)
7 (1.4)

5 (0.8)
46 (7.8)
19 (3.2)
<5 (<0.8)
12 (2.0)

<5 (<1.0)
<5 (<1.0)

<5 (<0.8)
11 (1.9)

Gender
Male
Female
Prefer not to say/non-binary
Not answered

111 (21.5)
391 (75.8)
<5 (<1.0)
10 (1.9)

109 (18.5)
468 (79.3)
8 (1.4)
<5 (<0.8)

Age
Under 18
18–35
36–49
50–69
70 +
Prefer not to say
Not answered

6 (1.2)
132 (25.6)
201 (40.0)
146 (28.3)
19 (3.7)
<5 (<1.0)
8 (1.6)

6 (1.0)
154 (26.1)
263 (44.6)
173 (29.3)
14 (2.4)
5 (0.8)
<5 (<0.8)

Ethnic or cultural background*
Indigenous/First Nations/Métis/Inuit
Arab
Black
Caucasian
Chinese
Filipino
Japanese
Korean
Latin American
Pacific Islander
South Asian
Southeast Asian
West Asian
Other
Prefer not to say

15 (2.9)
6 (1.2)
12 (2.9)
406 (78.7)
8 (1.6)
<5 (<1.0)
<5 (<1.0)
<5 (<1.0)
9 (1.7)
<5 (<1.0)
9 (1.7)
6 (1.2)
<5 (<1.0)
34 (6.6)
9 (1.7)

19 (3.2)
8 (1.4)
15 (2.5)
480 (81.4)
9 (1.5)
<5 (<0.8)
<5 (<0.8)
<5 (0.8)
10 (1.7)
<5 (<0.8)
9 (1.5)
5 (0.8)
<5 (<0.8)
20 (3.4)
23 (3.9)

Province
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland
Nova Scotia
Nunavut
Ontario
Prince Edward Island
Quebec
Saskatchewan
Yukon and Northwest Territories
Not answered

32 (6.2)
8 (1.6)
17 (3.3)
8 (1.6)
6 (1.2)
20 (3.9)
<5 (<1.0)
295 (57.2)
<5 (<1.0)
52 (10.0)
15 (2.9)
<5 (<1.0)
59 (11.4)

51 (8.6)
68 (11.5)
51 (8.7)
10 (1.7)
18 (3.1)
24 (4.1)
<5 (<0.8)
238 (40.3)
9 (1.5)
23 (3.9)
17 (2.9)
<5 (<0.8)
80 (13.6)

Respondent type
Person with epilepsy or seizures
Caregiver/former caregiver of someone with
epilepsy or seizures
Friend/family member of someone with
epilepsy or seizures
Healthcare provider
Representative of a community epilepsy agency
Other
Not answered

3. Results
All submitted questions will be made publicly available on the
OBI’s central database, Brain-CODE (braincode.ca).
In the initial survey, a total of 509 respondents submitted 2126
unique uncertainties (Fig. 2). Following the development of summary questions, 198 questions underwent the evidence check. Of
these, 61 were determined to be answered, 27 partially answered,
and 110 unanswered. Partially answered questions were rewritten
to include only those aspects which were unanswered and five
were subsequently merged with similar unanswered questions.
Thus, of the 198 summary questions, 132 were classified as unanswered following the evidence check. This list was further refined
by merging similar questions, producing a total number of 161
summary questions and 95 verified uncertainties. Following the
removal of low-frequency submissions, a shortlist of 43 questions
was included in the interim prioritization.
Five hundred and ninety responses were received to the interim
ranking survey. Across the initial and interim surveys, the majority
of respondents were PWE (49.4% and 42.5%, respectively), female
(75.8% and 79.3%), from Ontario (57.2% and 40.3%) and aged 36–
49 (40% and 44.6%) (Table 3). Most respondents denoted their ethnic background as Caucasian (78.7% and 81.4%), in accordance with
national demographic data suggesting that 77% of Canadians identify as Caucasian [17].
Table 4 displays the final rankings. As the priorities from the
two respondent groups (PWE/caregivers and healthcare providers)
were considered and ranked separately following the interim survey, the final shortlist of 16 questions was selected to ensure that
the top 10 ranked questions from both groups were brought forth
to the prioritization workshop.
In the final top 10 list (Table 4), the consensus highest priority
question was how genetic markers can be used in diagnosis and
treatment. The second highest-ranked question related to longterm impacts and side effects of antiseizure drugs (ASDs), which
was also ranked as the top priority for both respondent groups in
the interim survey. One question related to the effectiveness of
surgical treatment in both pediatric and adult populations. The etiology, diagnosis, and long-term impact of seizures were also
ranked in the top ten. Other questions were focused on the causes
of memory impairments and behavioral problems, sudden death in
epilepsy, and ASD polytherapy.

Healthcare providers
Family doctor
Specialist
Nurse or nurse practitioner
Pharmacist
Allied health professional (e.g., physician
assistant, social worker, psychologist,
occupational or physical therapist, midwife)
Other
Not answered

4. Discussion
This PSP brought together PWE, caregivers, and healthcare providers across Canada to determine priority areas of focus for
research on pediatric and adult epilepsy. The top 10 priorities
reflect the continued challenges in diagnosing, treating, and
managing epilepsy, which includes both seizures and the behavioral, cognitive and psychosocial aspects of the condition. Among
the top 16 questions from the interim survey, reducing the risk of
SUDEP, managing behavioral issues, and initiating ASD polytherapy were all ranked more highly by healthcare providers, while
non-drug lifestyle treatments, mood changes, and the links

*
Selection of more than one category was permitted. Demographic categories
with between 1 and 5 respondents are indicated as <5 to ensure privacy.

between hormones, seizures, and pregnancy were ranked more
highly by patients and caregivers. Despite these differences, there
was meaningful congruence between the two groups on several
questions prior to the workshop (Tables 4 and 5).
5
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Table 4
Top 10 list of research priorities and interim rankings.
Final
ranking

Interim survey ranking
Patients/caregivers

Healthcare
professionals

1

7

3

Can genetic markers be used
to diagnose and treat
epilepsy and seizure
disorders?

2

1

1

What are the impacts of
long-term use of antiseizure
drugs, the causes of side
effects of these treatments,
and how can we prevent the
side effects?

3

2

5

Question

What are the long-term
impacts of seizures on a
person’s brain, and overall
health and development?

4

13

6

How can the risk of SUDEP
(Sudden Unexpected Death
in Epilepsy) be reduced in
people with epilepsy?

5

16

12

What is the most effective
testing protocol for
determining causes of
seizures and/or a diagnosis of
epilepsy or other seizure
disorders and to reduce time
to diagnosis?

6

9

9

What are the brain changes,
on a cellular level, that lead
to seizure development?

7

11

11

How effective is surgical
treatment for adults and
children who experience
seizures/epilepsy?

8

3

4

What causes memory
problems associated with
seizures? Can these memory
problems improve over time,
and what are the best
treatment options for
memory loss in people who
experience seizures?

9

14

8

Aside from antiseizure drugs
and some brain lesions, what
causes behavioral changes in
people who experience
seizures? What is the best
way to treat behavioral
issues?

10

20

7

Table 5
Priority questions 11–16 with interim rankings.
Final
ranking

Interim survey ranking
Patients/caregivers

Healthcare
professionals

11

5

28

How do seizures impact the
mood of people who
experience them and what
are the best methods to
manage mood swings?

12

4

2

Are cannabis products (e.g.
marijuana, CBD oil) a safe
and effective treatment for
seizures alone or in
combination with standard
treatments (e.g. antiseizure
drugs)?

13

8

17

Is there a relationship
between hormonal changes
(e.g. puberty, menopause,
pregnancy) and seizure onset
and/or frequency, and what
are the effects of seizures
during pregnancy?

14

12

10

Is it safe to wean a person
who has experienced
seizures off of antiseizure
drugs and if so, when is the
right time to wean off
antiseizure drugs?

15

10

19

What are the best ways to
support people who
experience seizures secure
and perform in employment
(e.g., through
accommodations) and what
interventions can reduce
workplace discrimination?

16

6

13

What non-drug lifestyle
treatments (e.g.,
cardiovascular exercise,
yoga) are effective for
controlling seizure frequency
with or without standard
treatments (e.g., antiseizure
drugs)?

Question

ASDs. As with other priorities in the top 10 that are focused on
broad themes, this is a multi-part question that encompasses both
the impact of side effects and their prevention. Interestingly, the
only previously published exercise in epilepsy priority setting, a
series of focus groups organized in Wales, also found that the
top-ranked treatment uncertainty among Welsh people related to
side effects of ASDs [19]. Despite being the first-line therapy for
epilepsy, ASD selection is an inexact science, as the efficacy of a
particular drug is impossible to predict in individual patients.
30% of patients have seizures that fail to respond to ASDs, and
despite the introduction of more than a dozen new ASDs in the
past decade, this number remains unchanged [20]. Even when seizure control is achieved, the adverse effects of drug treatment can
be considerable, and are a leading cause of treatment failure [21].
Indeed, questions focused on alternative therapies, such as medical
cannabis and lifestyle treatments were also among the top 16.
Most questions in the top ten relate to diagnosis and etiology, seizure control, and QOL, which are necessarily interrelated. Misdiagnosis or delayed diagnosis may have serious implications and can
prevent initiation of appropriate and effective treatment [22,23],
which directly correlates to QOL [24,25]. Priority #4 addresses
SUDEP, or sudden unexpected death in epilepsy, which occurs

What is the efficacy (i.e., the
effectiveness of reducing
seizures) of adding a second
antiseizure medication
compared to changing to a
different antiseizure
medication? How can we
determine which
combinations of antiseizure
drugs are effective?

The consensus priority question was how genetic markers can
be used in diagnosis and treatment. Research continues to uncover
the genetic traits linked to seizure development, and hundreds of
genes are now known to be related to epilepsy [18]. Several inherited and de-novo variants are recognized as pathogenic, particularly in the epileptic encephalopathies, and the therapeutic
potential of genetic sequencing is also of great interest. The second
highest-ranked question relates to managing the side effects of
6
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aftermath, it is helpful to highlight the flexibility and resilience of
such a model of engagement.

when an otherwise healthy person with epilepsy dies suddenly and
unexpectedly, and no clear cause of death can be found. Although
the search for SUDEP biomarkers is a promising field of research,
the biggest known risk factor is uncontrolled generalized tonicclonic seizures [26], highlighting the importance of seizure control.
Finally, questions about memory impairments were understandably ranked highly by both patients and care providers, as they
are difficult to manage clinically and are the most frequently
reported cognitive complaint among PWE [27,28]. As declines in
cognitive function and behavioral changes are linked to both
uncontrolled seizures [29,30] and ASD treatment (15,25), links
between priorities must again be emphasized. Interestingly, the
prevention of acquired epilepsy was not a major theme, possibly
because this accounts for a minority of cases, but perhaps also
reflecting that the survey captured the concerns of those already
living with epilepsy. However, questions about prevention are
inherent in understanding the genetic causes of epileptogenesis
and the neuronal changes that lead to seizure development.
The categorization of a question as unanswered does not suggest the topic has not been investigated, but rather that the
strength of the evidence is not sufficient to reach a consensus.
For example, although the effectiveness of surgery has been widely
studied, most submissions focused on the reasons for failed surgeries and the prediction of post-surgical outcomes, about which
considerably less is known [31]. Similarly, although there is consensus on the optimal timing of ASD withdrawal in children, there
is insufficient evidence to determine this in the adult population
[32]. Nevertheless, the categorization of 66 of the original 161
summary questions as ‘‘answered” suggests that greater efforts
are needed to effectively translate existing knowledge to the epilepsy community. As described in the knowledge-to-action framework, identifying a knowledge gap is the first step in a cycle that
involves developing contextually relevant tools or interventions
for specific audiences, evaluating the impact, and ultimately ending with sustained knowledge use by stakeholders [33]. Current
and future knowledge translation tools, including a plain language
report on the PSP process and results can be found at braininstitute.ca/epilepsy-psp.
Although the JLA has completed over 100 formal PSPs globally,
this is the first to address epilepsy and seizures. While the results
reflect the Canadian perspective, given similar health service delivery models, access to care and burden of epilepsy across many
high-income countries [34,35], there is likely considerable overlap
with other populations. Another epilepsy PSP in the United Kingdom is currently in progress, which may provide an indication of
the generalizability across countries. However, as 80% of epilepsy
cases occur in low- and middle- income countries [36], where
infectious etiologies predominate and the majority lack access to
treatment, research priorities may differ substantially in
resource-poor settings. Importantly, the societal impact of seizures
extends beyond the clinical impact. The authors also note the
importance of many other topics raised in the surveys to the health
and well-being of PWE, such as addressing societal stigma,
employment issues, and coordination of care, and thus researchers
are encouraged to look beyond the top 10 priorities for potential
areas of focus.
The emergence of the COVID-19 pandemic halfway through the
PSP process posed many logistical and personal challenges. Not
surprisingly, these impacted on the PSP and the SG, such as the
inability to meet in person as planned, impact on clinical workloads, the availability of care and support for family members,
and the option to distribute information about the PSP in person.
However, it also presented opportunities for innovation and adaptability as new paradigms for virtual engagement emerged, including growing familiarity with videoconferencing facilities. As future
PSPs also navigate through the challenges of the pandemic and its

4.1. Limitations
Certain limitations should be considered when interpreting
these results. Survey respondents were largely limited to Englishor French-speaking Canadians with internet access, suggesting a
possible nonresponse bias associated with geographic or socioeconomic disparities. In the move to virtual engagement, PSPs should
be mindful of who they might not be reaching in their target population(s) and make efforts to close these gaps. Although the composition of the steering group was heterogenous in terms of
ethnicity, gender, age, and location in order to represent a range
of perspectives, many minority and marginalized groups, as well
as those aged under 18 and over 70, were underrepresented in
the survey results, and thus the final list of priorities may not fully
reflect the views of the diverse Canadian population. Clinical best
practices, availability of diagnostic testing, and access to specialists
can vary widely across the country, and systematic inequities exist
on a regional scale, particularly in the Arctic territories and among
Indigenous populations [37].
As with any non-random sample, some degree of self-selection
bias is assumed in survey respondents, and this is not meant to be
a definitive top 10 list. Rather, the strength of the JLA approach lies
in its dialogue-based model of consensus development. The final
workshop enables a unique exchange of knowledge and perspective and critically, shared decision-making between those with
lived and professional experience. Given the limited engagement
of patients and clinicians in setting epilepsy research agendas to
date, these results provide valuable insight into consensus priority
topics to guide patient-oriented research in epilepsy and seizures.
5. Conclusions
The results of this PSP provide a focus for epilepsy research
across the spectrum and lifespan of the disease. The priorities identified by the community serve as a valuable tool to help guide
patient-oriented research with the aim of improving clinical care
and management of epilepsy. The top 10 list affords an opportunity
for researchers and funders to better align their agendas with the
needs of PWE and their caregivers.
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